CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry, Nirali N. Shah, Rimas J. Orentas, Maryalice Stetler‐Stevenson, Constance M. Yuan, Sneha Ramakrishna, Pamela L. Wolters, Staci Martin, Cindy Delbrook, Bonnie Yates, Haneen Shalabi, Thomas J. Fountaine, Jack F. Shern, Robbie G. Majzner, David F. Stroncek, Marianna Sabatino, Yang Feng, Dimiter S. Dimitrov, Ling Zhang, Sang M. Nguyen, Haiying Qin, Boro Dropulić, Daniel W Lee, Crystal L. Mackall
Topics & Concepts
CD22CD19ImmunotherapyMedicineAntigenChimeric antigen receptorImmunologyB cellInternal medicineRefractory (planetary science)Cancer researchBiologyAntibodyImmune systemAstrobiologyCAR-T cell therapy researchImmune Cell Function and InteractionSilicon Carbide Semiconductor Technologies